Stocktoria
Phio Pharmaceuticals Corp. PHIO
Phio Pharmaceuticals Corp. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $21,000 | $138,000 | $15,000 | $19,000 |
| R&D expense | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M | -$8.8M | -$9.0M | -$7.4M | -$14.1M | -$9.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.6M | $0 |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M | -$8.8M | -$8.9M | -$7.4M | -$12.5M | -$9.0M |
| EPS (diluted) | — | $-9.08 | $-46.76 | $-10.10 | $-12.43 | — | — | — | — | — |
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M | -$8.8M | -$8.6M | -$7.5M | -$9.5M | -$7.8M |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M | -$8.8M | -$8.7M | -$7.5M | -$9.7M | -$7.8M |
| Cash & equivalents | $21.0M | $5.4M | $8.5M | — | — | — | — | — | $3.6M | $12.9M |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M | $15.7M | $8.0M | $15.3M | $4.1M | $13.4M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M | $2.7M | $2.3M | $1.7M | — | — |
| Shareholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M | $13.0M | $5.7M | $13.6M | $1.8M | $10.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | -100.0% | -84.8% | +820.0% | -21.1% | -44.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.